**Exhibit 99.5**

 
|   |                              | Axcan  Pharma inc.                |
|--------|-----------------------------------|-----------------------------------|
|        |                              | 597,  boulevard Laurier           |
|   | Mont-Saint-Hilaire  (Québec) |
|   |                              | Canada  J3H 6C4                   |
|   |                              |                              |
|   |                              | Tél.:  (450) 467-2600        |
|   |                              | 1-800-565-3255                    |
|   |                              | Téléc.:  (450) 464-9979 |
|   |                              |                              |
|   |                              | www.axcan.com                     |

 

**CERTIFICATION PURSUANT TO 17 CFR 240.13A-14**

**PROMULGATED UNDER SECTION 302 OF THE SARBANES-OXLEY ACTOF 2002**

 

I, Dr. Frank Verwiel, President and ChiefExecutive Officer of Axcan Pharma Inc. certify that:

 

1.               I have reviewedthis annual report on Form 40-F of Axcan Pharma Inc.;

 

2.               Based on myknowledge, this report does not contain any untrue statement of a material factor omit to state a material fact necessary to make the statements made, inlight of the circumstances under which such statements were made, notmisleading with respect to the period covered by this report;

 

3.               Based on myknowledge, the financial statements, and other financial information includedin this report, fairly present in all material respects the financialcondition, results of operations and cash flows of the issuer as of, and for,the periods presented in this report;

 

4.               The issuer’sother certifying officer and I are responsible for estabilishing andmaintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and15d-15(e)) for the issuer and we have:

 

(a)    Designed such disclosure controls andprocedures, or caused such disclosure controls and procedures to be designedunder our supervision, to ensure that material information relating to theissuer, including its consolidated subsidiaries, is made known to us by otherswithin those entities, particularly during the period in which this report isbeing prepared;

 

(b)    Designed such internal control overfinancial reporting, or caused such internal control over financial reportingto be designed under our supervision, to provide reasonable assurance regardingthe reliability of financial reporting and the preparation of financialstatements for external purposes in accordance with generally acceptedaccounting principles;

 

(c)    Evaluated the effectiveness of the issuer’sdisclosure controls and procedures and presented in this report our conclusionsabout the effectiveness of the disclosure controls and procedures, as of theend of the period covered by this report based on such evaluation; and

 

(d)    Disclosed in this report any change in theissuer’s internal control over financial reporting that occurred during theperiod covered by the annual report that has materially affected, or isreasonably likely to materially affect, the issuer’s internal control; and

 

5.               The issuer’sother certifying officer and I have disclosed, based on our most recentevaluation of internal control over financial reporting, to the issuer’sauditors and the audit committee of the issuer’s board of directors (or personsperforming the equivalent functions):

 

(a)    All significant deficiencies and materialweaknesses in the design or operation of internal control over financialreporting which are reasonably likely to adversely affect the issuer’s abilityto record, process, summarize and report financial information; and

 

(b)    Any fraud, whether or not material, thatinvolves management or other employees who have a significant role in theissuer’s internal control over financial reporting.

 

December 18, 2007(signed)

 

Frank Verwiel, M.D.

President and Chief Executive Officer

 

----